Comparative in vitro activity of garenoxacin against Chlamydia spp. | Zendy

Manuela Donati | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative in vitro activity of garenoxacin against Chlamydia spp.

Author(s) -

Manuela Donati

Publication year - 2002

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkf145

Subject(s) - chlamydia , microbiology and biotechnology , in vitro , antibacterial agent , chlamydiaceae , chemistry , biology , antibiotics , immunology , biochemistry

The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research